TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07819097: AN INTERVENTIONAL PHASE 3 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN PARTICIPANTS 60 YEARS OF AGE AND OLDER

Sponsor: Pfizer · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 600 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$15,676,800

Rescue Site Savings

+$10,336,890

Unlock Full NCT07819097 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07819097 Rescue Dossier →